Aiforia selected to provide AI solutions for breast and prostate cancer diagnostics for Fimlab Laboratories
Fimlab Laboratories Ltd has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions.
Aiforia Technologies Plc, August 1, 2024 at 09:00 am EEST — Fimlab Laboratories Ltd has selected Aiforia Technologies Plc as the provider for breast and prostate cancer diagnostics solutions. Fimlab is Finland’s largest healthcare laboratory company, owned by the wellbeing services counties of Pirkanmaa, Central Finland, Kanta-Häme, Ostrobothnia, and Päijät-Häme.
Earlier in May, Aiforia announced a framework agreement in which it was selected as one of the suppliers of AI solutions for Fimlab to support pathology diagnostics. Three best suppliers were chosen for AI models for nine applications and a development platform for AI models. Aiforia was qualified as one of the suppliers for eight applications and the development platform.
The AI solutions for breast and prostate cancer, representing three applications, are the first order for Aiforia within the multi-year framework agreement. The value of this first order for Aiforia is approximately EUR 300 thousand for the first year.
“We are extremely excited to officially kickstart this cooperation. Fimlab is a true pioneer in Finland in adopting AI solutions to support diagnostics in pathology. It is an honor to be part of this progressive step in our home country,” says Jukka Tapaninen, CEO of Aiforia.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient.
Find out more at www.aiforia.com
SOURCE: Aiforia
